ADAR1 Capital Management »

Aerovate Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Aerovate Therapeutics (AVTE) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Aerovate Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aerovate Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aerovate Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $470k 16k 29.57

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Aerovate Therapeutics

RA Capital Management
Sofinnova Ventures
TCG Crossover Management
Atlas Venture Life Science Advisors
Baker Bros. Advisors
Frazier Life Sciences Management
Cormorant Asset Management
Dr. Jeffrey R. Jay, M.D.
Driehaus Capital Management
BlackRock
Vanguard Group
OrbiMed Advisors
FMR
Eventide Asset Management
Octagon Capital Advisors

View all funds holding Aerovate Therapeutics